3. JUNE2015
A NEW COMPANY AIMING TO
DEVELOP BACTERIOPHAGE-BASED
THERAPIES FOR THE TREATMENT
AND PREVENTION OF DISEASES
STEMMING FROM THE
MICROBIOME.
3
MBCURE
4. JULY2015
RSeT™ is a defined medium that allows researchers to revert
human primed pluripotent stem cells to a naive-like state. RSeT™
also enables researchers to culture human naive-like pluripotent
stem cells long-term and supports this rapidly expanding field of
human pluripotent stem cell (hPSC) research.
4
STEMCELL
6. NOVEMBER2015 cont’d
A collaboration agreement allowing easy access
to Korean companies to WIS technologies.
6
KORIL-RDF
ImmunArray launches a new blood test for lupus
which is being rolled out nationally. This will provide a
wider group of rheumatologists with a simple,
accurate means for ruling out whether a patient is
suffering from the chronic, autoimmune disease that
affects 1.5 million Americans, mostly women between
the ages of 18 and 60.
ImmunArray
7. NOVEMBER2015 cont’d
AB2 Bio Ltd. achieved a medical breakthrough in
the treatment of systemic inflammation. Drug
candidate effective in treating a baby girl carrying
a newly identified, potentially fatal, genetic
mutation causing severe systemic inflammation.
7
AB2 BIO
IL1 8 BD WA S DIS COV E RED BY DR . DA NIE LA NOV IK
8. DECEMBER2015
WEIZMANN INSTITUTE DRUG, TOOKAD® SOLUBLE, APPROVED
FOR PROSTATE CANCER THERAPY IN MEXICO and ISRAEL
8
TOOKAD® SOLUBLE
A therapy invented at the Weizmann Institute of Science and clinically
developed in collaboration with Steba Biotech (France) has been
approved for the treatment of early-stage prostate cancer by Mexico’s
Secretariat of Health. The approval comes in the wake of the recent
successful completion of a Phase III clinical trial on more than 400
patients at 55 medical centers in 11 European countries, as well as a
confirmatory, Phase III study on 80 patients in Mexico.
9. DECEMBER2015 cont’
KADIMASTEM REACHED AGREEMENTS WITH THE
FDA REGARDING THE FRAMEWORK OF THE
CLINICAL TRIALS IN HUMANS FOR THE
TREATMENT OF ALS.
9
KADIMASTEM
10. DECEMBER2015 cont’d
Sun Pharmaceutical Industries Ltd. entered into
a tripartite research and option agreement with
Weizmann Institute of Science and Spain's Health
Research Institute of Santiago de Compostela
(IDIS) to develop breakthrough products for the
treatment of neurological diseases like brain
stroke; as well as glioblastoma.
10
SUNPHARMA
11. FEBRUARY2016
AWARDED FOR ITS "INNOVATION POTENTIAL" AT
THE INTERNATIONAL QUALITY INNOVATION OF
THE YEAR CEREMONY IN ESTONIA.
11
NEWCO2FUELS (NCF)
12. FEBRUARY2016
MERCK AND WEIZMANN INSTITUTE SIGN
NEW FRAMEWORK AGREEMENT ON
RESEARCH COLLABORATION
12
MERCK-WEIZMANN
AS PART OF THE NEW FRAMEWORK AGREEMENT
MERCK WILL FUND EACH OF THE TWO RESEARCH
AREAS WITH UP TO € 1 MILLION PER YEAR OVER
A 3-YEAR PERIOD.
13. MARCH2016
A NEW SPINOUT COMPANY RONDIX WAS BORN.
13
RONDINX
BASED ON THE WORK OF PROF. SEGAL AND PROF. ELINAV
NEXT GENERATION SEQUENCING AND
ANALYZING OF THE MICROBIOME.
14. MARCH2016
14
FROM A SINGLE PATENT
TO THREE DRUGS
$1,081 MILLION
Erbitux® Merck and Eli Lilly
metastatic colorectal cancer
$500 M (EST 2016)
Portrazza® Eli Lilly
Lung cancer
$359 MILLION
Vectibix® AMGEN
Colorectal cancer
Prof. Sela and colleagues
discovered that EGFR-
inhibiting antibodies
produce a synergistic
anticancer effect when used
together with
chemotherapy
The three EGFR blockers are
saving the lives of hundreds
of thousands of cancer
patients all over the world
EGFR
BLOCKERS
15. MARCH2016
NOVEL ANTIBODIES BASED THERAPIES
TARGETING MMP 9.
15
MABTRIX
BASED ON THE WORK OF PROF. IRIT SAGI
Core technology is based on a
molecular structure and
biophysics platform which
enables to identify and design
highly potent and extremely
selective monoclonal antibody
against a physiological
conformation of target
molecule
